Heat Biologics, Inc., a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, and its subsidiary, Pelican Therapeutics, have entered a manufacturing agreement with KBI Biopharma to advance cancer-targeting immunotherapies.    Last year, Pelican was awarded a $15.2 million grant from the Cancer Prevention and Research Institute of Texas to support manufacturing efforts, as well as to complete a 70-patient, Phase I trial. Under the agreement, K...